Current Opinion in Oncology最新文献_第8页

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-06 DOI: 10.1097/CCO.0000000000001121

引用次数: 0

Chemotherapy-induced nausea and vomiting: can we do better? 化疗引起的恶心和呕吐：我们能做得更好吗？

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-22 DOI: 10.1097/CCO.0000000000001114

Florian Scotté

{"title":"Chemotherapy-induced nausea and vomiting: can we do better?","authors":"Florian Scotté","doi":"10.1097/CCO.0000000000001114","DOIUrl":"10.1097/CCO.0000000000001114","url":null,"abstract":"Purpose of review: Although the management of nausea and vomiting induced by cancer treatments has evolved, several questions remain unanswered.Recent findings: New antiemetics have been developed these last decades with therapeutic indications to be defined according to the anticancer regimen and partly as a consequence of the assessment of individual patient risk factors. Guidelines still seem to have a low level of knowledge and compliance, with a role for scientific societies in term of dissemination and education. A number of persistent issues relating to emesis still need improvement in prevention and management. Nausea remains a subjective semantic whose evaluation should possibly benefit from educational programs. The risk classification of anticancer drugs must be regularly updated, requiring regular literature reviews and the integration of data from clinical trials relating to emerging anticancer drugs. Recent data, particularly in the context of emerging drugs, highlight the importance to consider emesis' impact beyond the 5-day period, with a potential adaptation of antiemetic prophylaxis, including the mode of administration of oral drugs.Summary: Guidelines update is presented with literature answers to the current issues in order to improve quality of patient's management in the context of emesis related to anticancer therapies.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"158-162"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peripheral neuropathy: from guidelines to clinical practise. 周围神经病变：从指南到临床实践。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-15 DOI: 10.1097/CCO.0000000000001112

Berit Jordan, Franziska Jahn, Karin Jordan

{"title":"Peripheral neuropathy: from guidelines to clinical practise.","authors":"Berit Jordan, Franziska Jahn, Karin Jordan","doi":"10.1097/CCO.0000000000001112","DOIUrl":"10.1097/CCO.0000000000001112","url":null,"abstract":"Purpose of review: Chemotherapy-induced peripheral neuropathy (CIPN) is a substantial adverse effect of anticancer therapy. No effective preventive strategies are established in clinical routine, although some forms of cryotherapy or compression therapy seem to be promising. CIPN is difficult to grade objectively and has mostly relied on a clinician- or patient-based rating that is subjective and not easily reproducible.Recent findings: Recent preclinical and clinical studies showed an indicative hint of serum neurofilaments for axonal damage as a biomarker and might be introduced in clinical practice in the future. Axonal degeneration in toxic neuropathy is triggered by molecular pathways including SARM1. Presence of certain genotypes predispose for developing severe vincristine neuropathy. Still, treatment of CIPN is focused on treating neuropathic pain primarily based on physicians experience. A positive effect of membrane stabilizers such as gabapentinoids could not be shown in a systematic review mostly due to inconsistent study populations. In the treatment and prevention of functional disability, physical exercise including sensorimotor-training and whole-body vibration seems promising.Summary: More research is needed on quantification of biomarkers indicative for axonal degeneration prior to CIPN symptom expression. All these recent findings should support the health-care team for a patient centred treatment approach.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"168-174"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer-associated thrombosis: what is new? 癌症相关血栓：有什么新进展？

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-16 DOI: 10.1097/CCO.0000000000001125

Isabelle Mahé, Samuel Benarroch, Sadji Djennaoui, Rabiaa Hakem, Abdallah Ghorbel, Hélène Helfer, Jean Chidiac

{"title":"Cancer-associated thrombosis: what is new?","authors":"Isabelle Mahé, Samuel Benarroch, Sadji Djennaoui, Rabiaa Hakem, Abdallah Ghorbel, Hélène Helfer, Jean Chidiac","doi":"10.1097/CCO.0000000000001125","DOIUrl":"10.1097/CCO.0000000000001125","url":null,"abstract":"Purpose of review: The life expectancy of patients suffering from thrombosis associated with cancer has improved significantly, making them a chronic disease. Patients with thrombosis and cancer are fragile. Treated with anticoagulants, they remain at risk of complications.Recent findings: Consequently, news issues emerge for clinical practice: anticoagulation therapy personalization is required to optimize the benefit ratio, involving patient characteristics and cancer characteristics. During follow-up, prediction score are designed and investigated to help identify and discriminate patients at risk of venous thromboembolism recurrences and major bleedings. Considering the improved prognosis of patients with cancer and cancer-associated thrombosis, the question of extended treatment arises, representing a major unmet need to date. Finally, new strategies, in particular anti-XI agents that appear attractive options, are currently being evaluated in the treatment of thrombosis associated with cancer.Summary: The improved prognosis of patients with cancer-associated thrombosis is accompanied by new therapeutic strategies to improve the benefit-risk ratio of anticoagulant treatment in these fragile patients, at risk of both venous thromboembolic recurrence and haemorrhagic complication.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"150-157"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging toxicities in oncology. 肿瘤学新出现的毒性。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-15 DOI: 10.1097/CCO.0000000000001122

Didier Mayeur

引用次数: 0

Prophylactic cranial irradiation for small cell lung cancer in the era of immunotherapy and molecular subtypes. 免疫治疗和分子亚型时代小细胞肺癌的预防性颅脑照射。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-12-02 DOI: 10.1097/CCO.0000000000001111

Veronika Pozonec, Maria Dorothea Pozonec, Clemens Aigner, Joachim Widder, Kristiina Boettiger, Zsolt Megyesfalvi, Balazs Dome

{"title":"Prophylactic cranial irradiation for small cell lung cancer in the era of immunotherapy and molecular subtypes.","authors":"Veronika Pozonec, Maria Dorothea Pozonec, Clemens Aigner, Joachim Widder, Kristiina Boettiger, Zsolt Megyesfalvi, Balazs Dome","doi":"10.1097/CCO.0000000000001111","DOIUrl":"10.1097/CCO.0000000000001111","url":null,"abstract":"Purpose of review: Small cell lung cancer (SCLC) is an aggressive disease with a poor prognosis, whereas its metastatic capacity carries a predilection for the brain. Although prophylactic cranial irradiation (PCI) has been used to address this problem, upcoming alternatives might necessitate reflection of its application in SCLC treatment.Recent findings: The addition of immunotherapy to treatment guidelines has provided a new strategy for the management of brain metastases. Complementation of immunotherapy with active MRI surveillance could potentially replace PCI and avoid irradiation-related cognitive side effects. SCLC's molecular profile is heterogeneous, with differential response to treatment modalities between subgroups. Investigation of these variances might be essential to improve therapeutic outcomes in SCLC patients.Summary: The role of PCI in SCLC treatment must be examined in light of immunotherapy. We summarize recent results, bearing SCLC subtypes and therapeutic vulnerabilities in mind, to derive tailored treatment strategies for SCLC patients in future settings.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"37 1","pages":"27-34"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-10-09 DOI: 10.1097/CCO.0000000000001103

Kris G Poppe, Aglaia Kyrilli, Giuseppe Costante

{"title":"Pregnancy-related hormonal changes and thyroid growth: do they have an impact on the higher incidence of differentiated thyroid cancer in women?","authors":"Kris G Poppe, Aglaia Kyrilli, Giuseppe Costante","doi":"10.1097/CCO.0000000000001103","DOIUrl":"10.1097/CCO.0000000000001103","url":null,"abstract":"Purpose of review: To analyze whether pregnancy could play a role in the higher prevalence of differentiated thyroid carcinoma (DTC) in women. Estrogens strongly modify thyroid economy by increasing iodine clearance, thyroid hormone requirement and production. Human chorionic gonadotropin (hCG) contributes to the increased thyroid hormone synthesis. Both estrogens and hCG can interfere with the regulation of thyroid volume and with thyroid nodule development and progression. The potential effect of hCG is exclusively related to its weak agonistic activity on TSH receptor. Estrogen implication on normal and nodule-derived thyrocyte growth has been demonstrated in vitro and in animal models. Furthermore, there is solid clinical evidence showing a promoting effect of pregnancy on thyroid volume and nodule development. Two metaanalyses, one including retrospective and another prospective observational studies, failed to show an association between pregnancy and DTC.Recent findings: A large pooled prospective analysis using multivariable-adjusted Cox proportional hazard models did not demonstrate an association between DTC and parity. Similarly, no association between PTC occurrence and parity was observed in a prospective cohort analysis by linkage to the statewide Surveillance, Epidemiology, and End Results (SEER).Summary: The presently available evidence does not support an involvement of pregnancy in DTC etiology.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"1-6"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introductions. 编辑介绍。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI: 10.1097/CCO.0000000000001109

引用次数: 0

Perioperative immunotherapy in nonsmall cell lung cancer. 非小细胞肺癌围手术期免疫疗法。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-09-05 DOI: 10.1097/CCO.0000000000001098

Renzhi Zhang, Chun Zou, Liang Zeng, Yongchang Zhang

{"title":"Perioperative immunotherapy in nonsmall cell lung cancer.","authors":"Renzhi Zhang, Chun Zou, Liang Zeng, Yongchang Zhang","doi":"10.1097/CCO.0000000000001098","DOIUrl":"10.1097/CCO.0000000000001098","url":null,"abstract":"Purpose of review: To evaluate and summarize the current clinical efficacy, safety, treatment patterns, and potential biomarkers, to guide future treatment strategies for nonsmall cell lung cancer (NSCLC), improve patient prognosis, and provide a scientific basis for personalized therapy.Recent findings: In recent years, the class of immune checkpoint inhibitors (ICIs), with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors at the helm, has catalyzed groundbreaking advancements within the perioperative treatment milieu for NSCLC. With the positive results of several phase III clinical trials, perioperative immunotherapy has been confirmed to significantly reduce the risk of postoperative recurrence in resectable NSCLC, becoming the new standard for perioperative treatment of stages II to III NSCLC. With the advent of the perioperative immunotherapy era, clinical issues such as the selection of the treatment population, the choice of regimen, the duration of treatment, whether patients with pCR need further adjuvant therapy, and the comprehensive management of patients throughout the perioperative period have attracted widespread attention.Summary: The perioperative treatment of NSCLC has fully entered the era of immunotherapy. Multiple clinical studies have confirmed that perioperative immunotherapy can significantly improve the survival benefit of resectable stages II to III NSCLC, establishing a new standard for the perioperative treatment of stages II to III NSCLC.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"40-47"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative immunotherapy for nonsmall cell lung cancer. 非小细胞肺癌围手术期免疫疗法。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-09-25 DOI: 10.1097/CCO.0000000000001100

Jingya Huang, Wenyuan Li, Hui Guo

{"title":"Perioperative immunotherapy for nonsmall cell lung cancer.","authors":"Jingya Huang, Wenyuan Li, Hui Guo","doi":"10.1097/CCO.0000000000001100","DOIUrl":"10.1097/CCO.0000000000001100","url":null,"abstract":"Purpose of review: Recent years have witnessed significant advancements in the treatment of lung cancer with immunotherapy, primarily centered on immune checkpoint inhibitors (ICIs). Numerous clinical studies have evaluated or are currently evaluating the clinical benefits of neoadjuvant, adjuvant, and perioperative use of ICIs. These findings have notably reshaped the landscape of perioperative treatment for nonsmall cell lung carcinoma (NSCLC).Recent findings: Comparing different treatment modes, adding ICIs in the adjuvant phase to neoadjuvant treatment with ICIs and chemotherapy may not improve survival outcomes for patients with resectable NSCLC and may be associated with increased adverse events. For prognostic factors, ctDNA minimal residual disease (MRD) status might serve as an early predictor of achieving pathological remission. For study endpoints, a positive result with PFS as the primary endpoint may not necessarily translate into overall survival benefits.Summary: For perioperative immunotherapy, challenges persist, including the current lack of sensitive and reliable biomarkers, the effect of neoadjuvant therapy on surgical risk as well as the selection of the appropriate study endpoint. In this review, we discuss recent and ongoing trials investigating strategies of neoadjuvant, adjuvant and perioperative immunotherapy in NSCLC, while also proposing considerations for future directions in this continuously evolving field.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"63-72"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0